Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 6 Issue 10, October 2007

In This Issue

Top of page ⤴

Editorial

Top of page ⤴

News and Analysis

Top of page ⤴

News in Brief

Top of page ⤴

Patent Watch

Top of page ⤴

From the Analyst's Couch

Top of page ⤴

Fresh from the Pipeline

    • Helmy M. Siragy
    • Santwana Kar
    • Peter Kirkpatrick
    Fresh from the Pipeline
Top of page ⤴

Research Highlight

Top of page ⤴

In Brief

Top of page ⤴

Opinion

Top of page ⤴

Review Article

  • Retinoic acid receptors (RARs) are ligand-controlled transcription factors that function as heterodimers with retinoid X receptors (RXRs) to regulate cell growth and survival. This article discusses recent advances in the understanding of the biological role of RARs and RXRs and their implications for the design of selective receptor modulators for cancer and metabolic diseases.

    • Lucia Altucci
    • Mark D. Leibowitz
    • Hinrich Gronemeyer
    Review Article
  • Retinoic acid receptors (RARs) are important drug targets for cancer therapy and prevention, and the potential of rexinoids for the treatment of metabolic diseases is increasingly being recognized. This article reviews recent structural data for RARs and retinoid X receptors (RXRs), discusses strategies in the design of selective RXR and RAR modulators, and consider lessons that can be learned for the design of selective nuclear-receptor modulators in general.

    • Angel R. de Lera
    • William Bourguet
    • Hinrich Gronemeyer
    Review Article
  • Chronic myeloid leukaemia caused by the mutant BCR–ABL kinase has been successfully treated with inhibitors of this kinase, such as imatinib, but mutations within the kinase can result in resistance to these drugs. Quintás-Cardama and colleagues discuss novel BCR–ABL inhibitors that have the potential to overcome such resistance.

    • Alfonso Quintás-Cardama
    • Hagop Kantarjian
    • Jorge Cortes
    Review Article
Top of page ⤴

Careers and Recruitment

Top of page ⤴

Search

Quick links